Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymph omaki nase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.

MLA

Nuran Katgı, et al. “Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymph Omaki Nase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.” Thoracic Research & Practice, vol. 24, no. 4, July 2023, pp. 180–85. EBSCOhost, https://doi.org/10.5152/ThoracResPract.2023.22200.

APA

Nuran Katgı, Çimen, P., Akyol, M., Gürsoy, P., & Agüloğlu, N. (2023). Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymph omaki nase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib. Thoracic Research & Practice, 24(4), 180–185. https://doi.org/10.5152/ThoracResPract.2023.22200

Chicago

Nuran Katgı, Pınar Çimen, Murat Akyol, Pınar Gürsoy, and Nurşin Agüloğlu. 2023. “Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymph Omaki Nase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.” Thoracic Research & Practice 24 (4): 180–85. doi:10.5152/ThoracResPract.2023.22200.